

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Sigma Healthcare Limited ("Sigma")
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vikesh Ramsunder
Date of last notice	15 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The trustee of the SIG Employee Share Administration Trust is the registered holder of the shares. Mr. Ramsunder is the beneficial holder of the shares (he has been allocated the shares from the unallocated shares held in the trust).
Date of change	31 August 2026
No. of securities held prior to change	<u>Direct</u> 3,132,984 ordinary shares 1,010,723 2024 LTI Rights 813,449 2025 LTI Rights
Class	Performance shares (these are ordinary Sigma shares that are subject to certain restrictions under Sigma's Short Term Incentive Equity Deferral Plan until they have vested)
Number acquired	564,896
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	The shares were granted to Mr. Ramsunder for nil consideration. They were granted to him as part of his executive remuneration package.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> 3,132,984 ordinary shares 1,010,723 2024 LTI Rights 813,449 2025 LTI Rights <u>Indirect</u> 564,896 performance shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The shares were granted to Mr. Ramsunder pursuant to his FY26 STI. For further information see pages 42 to 47 of Sigma's 2026 Annual Report released to ASX on 27 August 2026 and Item 5.2 of the Explanatory Notes in Sigma's Notice of Annual General Meeting 2025 ("Grant of performance shares to Managing Director and Chief Executive Officer of Sigma under the Company's Short Term Incentive Equity Deferral Plan (STIEDP) (Resolution 6)").

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.